Journal
DERMATOLOGIC THERAPY
Volume 19, Issue 1, Pages 9-18Publisher
WILEY
DOI: 10.1111/j.1529-8019.2005.00051.x
Keywords
adjuvant therapy; high-risk melanoma; interferon-alpha; melanoma therapy
Categories
Ask authors/readers for more resources
Systemic adjuvant therapy in melanoma patients is the systemic treatment that is administered with the goal of eradicating micro metastatic deposits in patients who are clinically free of disease after surgical removal of the primary melanoma, but with a high risk of systemic recurrence. Interferon-alpha (IFN-alpha) is one of the most frequently used adjuvant therapies. Several randomized trials evaluated the efficacy of IFN-alpha in melanoma patients. However, results from conducted trials are controversial. Twelve randomized IFN-alpha trials are discussed in detail. All trials, including meta-analysis, failed to demonstrate a clear impact of IFN-alpha therapy on overall survival in melanoma patients. Based on currently available evidence, IFN-alpha therapy in the adjuvant setting should not be considered standard of care for patients who have melanoma. Results from ongoing studies are awaited. Further research for this therapy is required.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available